2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
118
Neoplasms
110
Lung Neoplasms
65
Colorectal Neoplasms
52
Prostatic Neoplasms
46
Carcinoma, Non-Small-Cell Lung
46
Pancreatic Neoplasms
34
Melanoma
33
Ovarian Neoplasms
29
Neoplastic Cells, Circulating
29
Head and Neck Neoplasms
27
Uterine Cervical Neoplasms
23
Multiple Myeloma
20
Glioma
20
Colonic Neoplasms
20
Sarcoma
19
Carcinoma, Hepatocellular
19
Leukemia, Myeloid, Acute
18
Neoplasm Metastasis
17
Lymphoma
15
Glioblastoma
15
Esophageal Neoplasms
15
Squamous Cell Carcinoma of Head and Neck
14
Hematologic Neoplasms
14
Leukemia
13
Endometrial Neoplasms
13
Myelodysplastic Syndromes
11
Kidney Neoplasms
11
Gastrointestinal Neoplasms
11
Carcinoma, Renal Cell
11
Interventions
Temozolomide
11
Cyclophosphamide
11
Radiotherapy
7
Magnetic Resonance Spectroscopy
6
Filgrastim
6
Cisplatin
6
Vincristine
5
Etoposide
5
Carboplatin
5
antineoplaston AS 2-1
4
antineoplaston A10
4
sargramostim
3
Thiotepa
3
Melphalan
3
Carmustine
3
Automobiles
3
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
3
gallium Ga 68 dotatate
2
fludarabine
2
dactolisib
2
aldesleukin
2
Thalidomide
2
TH 302
2
Surveys and Questionnaires
2
Paclitaxel
2
Irinotecan
2
Granulocyte Colony-Stimulating Factor
2
Gemcitabine
2
Gadolinium DTPA
2
Everolimus
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive
×
Blood Specimen Collection
×
Clear all
NCT06861244
2026-04-23
PNOC031
University of California, San Francisco
Phase 2
Recruiting
70 enrolled